gmp
gmp

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Center for International Blood and Marrow Transplant Research

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AAPS 2020 PHARMSCI 360

              Participation Not Confirmed

              Update your events

              CIBMTR Completes Enrollment in Yescarta® Long-Term Post-Marketing Safety Study

              Contact the Supplier

              Lead Product(s): Axicabtagene Ciloleucel,Cyclophosphamide,Fludarabine Phosphate

              Therapeutic Area: Oncology Product Name: Yescarta

              Highest Development Status: Phase IV Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 08, 2020

              Details:

              Yescarta is the first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

              Takeda Pharmaceutical

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              JAPAN Japan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AAPS 2020 PHARMSCI 360

              Participation Not Confirmed

              Update your events

              Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO in Multiple Myeloma as a First-Line Maintenance Therapy

              Contact the Supplier

              Lead Product(s): Ixazomib,Lenalidomide,Dexamethasone

              Therapeutic Area: Oncology Product Name: Ninlaro

              Highest Development Status: Phase IV Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 12, 2020

              Details:

              Positive Phase 3 Data Evaluating NINLARO as a Maintenance Therapy (TOURMALINE-MM4) Shows Significant Improvement in Progression-Free Survival in Adult Patients Not Treated with Stem Cell Transplantation.

              PharmaCompass__DigitalAd